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Summary Loss of chromosome 10 was observed in 10 out of 12 xenografted glioblastomas studied.
Chromosome 10 carries the gene coding the hexokinase type I isoenzyme (HK-I), which catalyses the first step
of glycolysis, which is essential in brain tissue and glioblastomas. We investigated the relationships between the
relative chromosome 10 number, the amount of HK-I mRNA, HK-I activity and its intracellular distribution,
and glycolysis-related parameters such as the lactate-pyruvate ratio, lactate dehydrogenase (LDH) and ATP
contents. Individual tumour HK-I mRNA amounts were 23-65% lower than that of normal human brain and
reflected the relative decrease of chromosome 10 number (ax<0.01). Total HK activities of individual
glioblastomas varied considerably but were constantly (a mean of seven times) lower than that of normal brain
tissue. The mitochondria-bound HK-I fraction of individual tumours was generally over 50%, compared with
that of normal brain tissue. As shown by lactate-pyruvate ratios, in all the gliomas, glycolysis was elevated to
an average of 3-fold that measured in normal brain. An elevated ATP content was also constantly noted.
Adaptation of glioblastoma metabolism to the chromosome 10 loss and to the HK-I transcription unit
emphasises the critical role ofglycolysis in their survival. We hypothesise that HK-I, the enzyme responsible for
initiating glycolysis necessary for brain function, may approach its lowest limit in gliomas, thereby opening
therapeutic access to pharmacological anti-metabolites affecting energy metabolism and tumour growth.
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Gliomas (glioblastoma multiforme) are the most common
primary brain tumours. Cytogenetic studies showed recurrent
losses of chromosome 10, gains of chromosome 7 and
structural alterations of chromosomes 9 and 22 (Bigner and
Mark, 1984; Bigner et al., 1988, 1990). According to these
different studies, chromosome 10 loss affects 90-95% of
gliomas. Loss of an entire chromosome or an arm is
suspected of being related to the loss of anti-oncogene(s),
which in turn would favour selective advantage, owing to the
expression of 'uncontrolled' oncogene(s). In the case of
chromosome 10 loss, the putative anti-oncogene is still
unknown, although it is being actively sought (Steck et al.,
1995). Chromosome 10 loss concomitantly leads to that of
transcription units of numerous metabolism-involved genes,
including some specifically involved in tumour cell metabo-
lism. Glucose is an important metabolic source of energy for
tumours, particularly for poorly differentiated and rapidly
growing ones that exhibit high rates of glycolysis (Pedersen,
1978). The hexokinase type I (HK-I)-encoding gene is located
on chromosome band 10q22 (Shows et al., 1989). HK-I,
(ATP:D-hexose 6-phosphotransferase, EC 2.7.1.1), one of
four mammalian HK isoenzymes, catalysing the phosphor-
ylation of glucose to glucose 6-phosphate (G-6-P), enables
glucose entry into glycolysis (Wilson, 1995). HK-I is either
free in the cytosol (cHK-I) or bound to the mitochondrial
outer membrane (mHK-I). HK binding could be a target for
therapy of gliomas and can be disrupted by therapeutic
agents (Oudard et al., 1995).
Under normal conditions, oxidative metabolism represents
virtually the sole pathway for generating the energy required
to support cerebral function (Sokoloff et al., 1977). Active
aerobic glycolysis is increased in tumour cells (Warburg,
1956) and, surprisingly, in spite of an HK-I gene deficiency,
gliomas are highly glycolytic (James et al., 1988). The present
investigation explored the relationships between the relative
chromosome 10 number, the amount of HK-I mRNA and
HK-I activity and its intracellular distribution and the
lactate-pyruvate ratio and lactate dehydrogenase (LDH)




Fifteen tumours obtained surgically from patients with
gliomas were transplanted subcutaneously into athymic nude
mice and maintained by serial transplantation from mouse to
mouse. Except for one tumour (TG-24-RO) described as a
grade III astrocytoma, all others were glioblastoma multi-
forme (GBM), according to Burger's histological classifica-
tion (Burger, 1986). Tumour tissues were harvested,
immediately frozen in liquid nitrogen, then stored at
-80°C. Experimental analysis was performed on xenografts
between passages 4 and 7. One histologically normal brain-
tissue sample (reference control) from a well-oxygenated
patient was taken during surgery and immediately immersed
in liquid nitrogen, then stored at - 80°C.
Cytogenetic analysis and chromosome 10 painting
Cells in metaphases were obtained in short-term cultures (1-
3 days) of xenografted gliomas. All karyotypes were
established after R-banding on at least ten metaphasic cells
per tumour. After identification of the rearranged chromo-
somes, we tried to determine the location of the breakpoints
and counted the number of copies of each chromosome or
chromosome segment. These data enabled us to estimate the
average number of copies of each chromosome per tumour.
The relative number of chromosomes 10 was defined as the
ratio of the number of chromosomes 10 multipled by 46
(total number of chromosomes per normal cell) to the mean
number of chromosomes in the tumour studied; the normal
ratio is 2.
Correspondence: MF Poupon
Received 6 October 1995; revised 6 March 1996; accepted 2 April
1996Glycolysis, hexokinase, chromosome 10 loss in gliomas
S Oudard et al
Chromosome painting was performed by in sittuhybridisa-
tion using human total genomic biotin-label painting probes
of chromosome 10 (Cambio, Biosys, Compiegne, France).
After overnight hybridisation with 10 M1 of the probe, slides
were rinsed in 50% formamide/2 x saline sodium citrate
(SSC) for 15 min at 43°C, and in 2 x SSC for 10 min at
60°C. For detection, slides were incubated first in goat anti-
biotin antibody, diluted 1:100 (Vector, Biosys), then in
rabbit fluorescein isothiocyanate-conjugated anti-goat anti-
body, diluted 1:200 (Cambio, Biosys): chromosomes were
counterstained with propidium iodide (0.3 yg ml-') for 3 min
and mounted in a solution of antifade p-phenylene diamine.
Slides were examined under a conventional epifluorescence
microscope (Leitz Aristoplan); metaphasic chromosomes were
photographed using Ektachrome ASA 400 film (Kodak).
Preparation of enzyme fractions
All the steps were performed at 4°C. The tissue samples were
thawed and immediately homogenised in a Potter homo-
geniser in a 10-fold excess of extraction buffer, containing
10 mM Tris-HCl (pH 7.7), 0.25 M sucrose, 1 mM dithiothrei-
tol, 1 mM aminocaproic acid and 1 mM phenylmethylsulpho-
nyl fluoride. The homogenate was centrifuged for 15 min at
800 g to remove cell debris. The pellet was washed once with
extraction buffer, while the 800 g supernatants were pooled as
the 'total hexokinase fraction' (tHK) and further prepared
according to Sprengers et al. (1983) with modifications. The
800 g supernatant pool was centrifuged for 15 min at
48 000 g. The 48 000 g supernatant was referred to as the
'cytosolic fraction' (cHK). The 48 000 g pellet was washed
once with extraction buffer. The HK activity in the final
pellet was referred to as 'the mitochondria-bound fraction'
(mHK).
Hexokinase activity assay
Enzyme activity was determined in a system coupled with G-
6-P dehydrogenase. A final volume of 1 ml of assay medium
contained 100 mM Tris-HCl (pH 8.0), 10 mM glucose,
0.4 mM NADP+, 10 mm magnesium chloride, 5 mM ATP
and 0.15 U G-6-P-dehydrogenase. The reaction was started
by addition of the extract sample at 340 nm in an Uvikon
810 CL spectrophotometer (Kontron, Basle, Switzerland).
One unit of HK activity was defined as the amount of
enzyme catalysing the formation of 1 Mmol of G-6-P per min
at 37°C. The protein content was measured using the BCA
protein assay (Pierce Chemical, Rockford, IL, USA). Specific
activities are expressed as mU mg-' protein. Before
determination of c- and mHK activities, all fractions were
incubated ice-cold with 0.1% Triton X-100 for 20 min. All
assays were run in triplicate.
L-Lactate dehydrogenase (LDH) activity assay
LDH (EC 1.1.1.27) activity was determined in cytosolic
extracts of 15 human xenografted gliomas and normal human
brain tissue, using the LDH optimised test (Sigma
Diagnostics, St Louis, MO, USA). The reaction was
monitored at 340 nm using a Kontron Uvikon 810 CL
spectrophotometer. Specific activity is expressed as mU mg-1
protein. One unit of LDH activity was defined as the amount
of enzyme that catalyses the formation of 1 ymol of lactate
per min at 37°C.
Lactate, pyruvate and ATP determinations
Lactate and pyruvate were assayed according to Vassault et
al. (1991). Before lactate detection, glutamate and alanine
aminotransferase were added to the sample to remove
endogenous pyruvate. The assays were run using a Cobas
Fara centrifugal automatic analyser (Diagnostica Roche, Ile
de la Jatte, France).
ATP bioluminescence was determined by using the
luciferin-luciferase reaction described by Lundin et al.
(1986).
RNA extraction and Northern blot analysis
Xenografted glioma samples that had been stored in liquid
nitrogen were pulverised while still frozen. Total RNA was
extracted with guanidium isothiocyanate and layered over
(5.7 M) caesium chloride in a solution of (25 mM, pH 5.0)
sodium acetate (Chigwin et al., 1979). Gradients were
Table I Clinicopathological characteristics, hexokinase content and activity measurements, transcript level and cytogenetic characteristics of
xenografted human gliomas
Modal Chromo- HK-I-
number of some 10 mRNA Lactate-
Histology chromo- number by transcript tHK cHK mHK mHK pyruvate ATP
Code gradea somes painting level activityd activityd activityd (%) ratio LDHd contente
Normal 46 E 1.2 489 115 374 76 5 1715 10
human
brain
Xenografts GBM/IV 51 E 0.78 76 19.4 57 75 27 ND 102
TG-18CH GBM/IV 46 E 0.77 76 69.3 7 9 15 1931 ND
TG-8-OZ GBM/IV 74 D ND 53 15.7 38 71 5 ND 13
TG-21-LA GBM/IV 82 D 0.28 173 52.7 120 69 22 1740 ND
TG-7-RO GBM/IV 47 D 0.43 155 52.3 103 66 10 1850 91
TG-15-HA GBM/IV 72 D 0.33 84 38.7 44.8 54 8 ND 18
TG-16-PE GBM/IV 46 D ND 79 27.6 51 65 24 1860 65
TG-17-MA GBM/IV 107 D 0.64 68 29.3 38.9 57 17 ND 44
TG-19-ME GBM/IV 69 D 0.52 39 19.5 19.4 50 26 1978 61
TG-9-TH GBM/IV 81 D 0.46 22 8.9 13.3 60 14 ND 44
TG-23-GI GBM/IV 46/88 D 0.62 73 59.5 13.3 18 11 2580 26
TG-11-DU GBM/IV 84 D 0.78 82 54.2 28.1 34 23 1950 81
TG-10-PY Astrocytoma/ 46 ND ND 17 7.9 9.2 54 ND 1820 19
TG-24-RO III
GBM/IV ND ND 0.34 34 26 8 23 ND 1745 25
TG-22-LU GBM/IV 46/85 ND 0.58 54 21.2 32.4 60 8 ND 71
TG-20-LA
Total mean 0.54 72 33.5 39 51.5 16 1939 50
(s.e.m.) +0.05 +11 +5 ±9 +5 +2 +254 ±8
aAccording to WHO classification. GBM, glioblastoma multiform. bE, euploid; D, deficient. CExpressed in arbitary units (AU). dExpressed in
mU mg 1 protein. eExpressed in nmolg 1 protein. ND, not done.centrifuged overnight in a Beckman SW41 rotor (Beckman
Instruments, Fullerton, CA, USA) at 33 000 r.p.m. Total
RNA (20 ,ug) was electrophoresed in 1% formaldehyde gels
and transferred onto nylon Hybond-N filters (Amersham,
Arlington Heights, IL, USA). The transfer was performed
essentially according to the procedure of Maniatis et al.
(1982). Baked filters were prehybridised for 18-24 h at 42°C.
The hybridisation buffer contained 50% formamide, 5 x SSC
(0.15 M sodium chloride, 0.015 M sodium citrate and 50 mM
disodium hydrogen phosphate-sodium dihydrogen phos-
phate (pH 6.5), Denhardt's solution (0.02% bovine serum
albumin, 0.02% polyvinylpyrrolidone and 0.02% Ficoll) and
100 mg ml-1 sonicated salmon sperm DNA. The probes were
labelled with [32P]deoxycytidine triphosphate (108 c.p.m. mg-I
DNA) by a random priming labelling system according to the
supplier's recommendations (Boehringer, Mannheim, Ger-
many). The following probes were used: HK-I (Nishi et al.,
1988) GAPDH (i.e. glyceraldehyde-3-phosphate-dehydrogen-
ase) and pBR322 (Fort et al., 1985). The HK-I probe was a
gift from Dr G Bell (Howard Hughes Medical Institute,
University of Chicago, IL, USA). Finally filters were washed
three times at room temperature in 2 x SSC and in 0.1%
sodium dodecyl sulphate for 1 h at 55°C. The radioactive
signal was measured in arbitrary units (AU) using a
phosphorimager (Molecular Dynamics, Sunnyvale, CA,
USA).
Statistical analysis
Arithmetic means and standard errors were calculated.
Student's t-test (two-tailed) was applied to enzyme data to
determine the probability (P) that the differences were
statistically significant. Correlation coefficients (R2) were
calculated according to Schwartz (1994) and were applied
to relative chromosome 10 number, the amount of HK-I
mRNA, HK-I activity and its intracellular distribution,
lactate-pyruvate ratio and ATP content to determine the
probability (a) that the differences were statistically
significant.
Results
Among the 15 different tumours xenografted into athymic
nude mice, 14 were histologically classified as GBM and one
as an anaplastic astrocytoma (TG-24-RO).
Chromosome 10 content
The karyotype could be established for 14 of the 15
xenografted gliomas. The relative chromosome 10 number
was determined using R-banding and was found to be low in
12 out of 14 cases. Chromosome 10 painting globally
confirmed the results obtained by R-banding analysis,
demonstrating a chromosome 10 deficiency in 10 of the 12
tumours studied (Table I). An example of chromosome 10
deficiency, assessed by painting of TG-15-HA cells in
metaphase, is shown in Figure la. However, gliomas, TG-
18-CH (Figure lb) and TG-8-OZ were not deficient for
chromosome 10. In TG-23-GI, apparently strongly lacking in
chromosome 10, chromosome painting demonstrated a
structural rearrangement (Figure 1c), not identifiable by
chromosome banding alone. In this hyperploid tumour, two
elements comprised both segments of chromosome 10, and
were duplicated. No normal chromosome 10 was observed.
Overall, a chromosome 10 deficiency was demonstrated in 10
out of 12 tumours studied by both chromosome banding and
painting, and in two other tumours studied by chromosome
banding alone.
Amount of HK-I mRNA
HK-I mRNA amounts in tumour extracts were semiquanti-
fied by Northern blot analysis and were compared with that
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of GADPH, used as an internal marker. To ensure that
mRNA quantification could be performed under
our experimental conditions, increasing concentrations
(2.5-20 gg) of TG-8-OZ extract were electrophoresed, then
blotted, hybridised with the [32P]HK-I probe and the
radioactive signal measured by a phosphorimager. A linear
correlation was obtained between the area under the curve
and the amount of HK-I mRNA (a<0.01, data not shown).
The individual HK-I mRNA amount in the 12 gliomas tested
ranged from 0.78 to 0.28 AU, whereas HK-I mRNA
expression in a normal human brain extract was 1.2. HK-I
mRNA was considered as decreased when below 0.6, i.e. less
than 50% of the control. Compared with normal human
brain, the HK-I mRNA transcript level was drastically
decreased in seven gliomas and somewhat less in the five
others. The two gliomas that retained their chromosomes 10
(TG-18-CH and TG-8-OZ) had more transcripts (0.78 and
Figure 1 Fluorescence in situ hybridisation on metaphase
chromosomes using human total genomic biotin-labelled painting
probes of chromosome 10 on three xenografted gliomas. (a)
Specific painting of TG-15-HA xenograft, a diploid clone,
revealed only one chromosome 10. (b) Specific painting of
euploid TG-18-CH xenograft detected two chromosomes 10. (c)
Specific painting of TG-23-GI xenograft showed a rearrangement
of chromosome 10.Glycolysis, hexokinase, chromosome 10 loss in gliomas
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0.77 respectively) than the others but still only 65% of the
normal brain control. The seven gliomas with low HK-I
mRNA amounts were chromosome 10 deficient. Indeed, a
significant correlation was found between the relative
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Figure 2 (a) Correlation between semiquantitative HK1 mRNA in arbitrary units (AU) and relative chromosome 10 number in 15
human xenografted gliomas and normal brain tissue control. (b) Correlation between semiquantitative HKI mRNA and tHK
activity. (c) Relationships between the percent of mitochondria-bound HK and mHK activity. (d) Relationships between the
lactate-pyruvate ratio and mHK activity. (e) Correlation between the lactate-pyruvate ratio and the ATP content. (f) Correlation
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HK enzymatic activity
Total HK-I activity (expressed in mU mg-' protein) and its
intracellular distribution were studied. Mean tHK activity
was constantly lower in gliomas (72+ 11 mU) than in the
normal human brain (489 mU, Table I). The intertumoral
tHK activity varied widely, ranging from 17 (TG-24-RO) to
173 mU (TG-7-RO), i.e. 3.5-35% that of the control. Mean
c- and mHK activates were respectively 3.4-fold and 9.6-fold
lower in gliomas than in controls.
Most HK was bound to mitochondria in normal brain
tissue (76%). In the majority of gliomas, HK was also mostly
bound to mitochondria, except for a group of four gliomas
TG-10-PY, TG-22-LU, TG-11-DU and TG-8-OZ whose
mHK fractions were of 34%, 23%, 18% and 9%. Number
of chromosome 10 was not correlated with HK activity as if
HK decrease precedes the loss of chromosome 10. A
correlation was established between tHK activity and the
amount of HK-I mRNA (a<0.05) (Figure 2b). A significant
correlation was also found between mHK fraction and mHK
activity (oc <0.05) in the xenografts (Figure 2c). This
relationship was no longer significant when the normal
brain value was included in the analysis.
Lactate-pyruvate ratio and ATP content
Lactate and pyruvate concentrations were measured and
lactate-pyruvate ratios were calculated for 13 gliomas (Table
I). The lactate-pyruvate ratio was 5 in control brain. The
intertumoral variations ranged from 5 to 27 (mean 16+2).
Except for TG-21-LA, this ratio was always higher in
xenografted tissues than in control brain, with a mean
increase of 5-fold. The higher lactate-pyruvate ratio was
independent of mHK activity (Figure 2d). The ATP content
(expressed in nmol g-' protein) was always higher in gliomas
in which, despite wide interindividual variations, a mean of
50 was measured compared with 10 in the control brain. The
higher ATP content was significantly correlated with the
lactate -pyruvate ratio (Figure 2e) (a<0.05) and mHK
activity when value for normal brain was not included
(Figure 2f) (ac<0.05).
L-Lactate dehydrogenase activity
LDH was included as a positive enzyme control. No
significant differences were observed in LDH activity in
human xenografted gliomas compared with normal human
brain tissue.
Discussion
Chromosome 10 loss has been described as a recurrent event
in advanced gliomas (Fujimoto et al., 1989; Watanabe et al.,
1990; Bondy et al., 1994). In our series of human xenografted
gliomas, homogeneous for histology and grading, cytogenetic
analyses with R-banding and chromosome painting con-
firmed the previous reports: chromosome 10 deficiency was
detected in 10 of the 12 gliomas studied. This loss is
paradoxical in these tumours which use glucose as their
main source of energy metabolism (Parry and Pedersen,
1990). To maintain a highlevel of glycolysis, we postulated
that gliomas either increased HK-I gene transcription or
increased HK enzymatic activity. We attempted here to
elucidate how gliomas adapt their glucose metabolism to
chromosome 10 deficiency.
Despite the limitations of semiquantification using the
Northern blotting technique, considerable differences between
HK-I mRNA amounts in normal control brain and gliomas
with or without a chromosome 10 deficit were measured.
Quantification by RT-PCR would have been more quantita-
tive; however, this technique was not performed because we
had already found an important and reproducible decrease in
HK-I mRNA by Northern blot in the whole glioma series. A
significant correlation was found between the relative
chromosome 10 number and the HK-I mRNA amount,
which suggests a gene dosage effect, as proposed by Lasserre
et al. (1994).
An alternative hypothesis to explain the decreased amount
of RNA, besides less HK-I mRNA transcription, would be a
more rapid degradation of the messenger RNA (shortening
its half-life). As a 50% decrease in HKI-mRNA was
associated with a recurrent loss of one copy of chromosome
10, no evaluation of HK-I mRNA increased degradation rate
was investigated. A multistep mechanism, involving chromo-
some loss and altered transcription, has previously been
proposed for superoxide dismutase II and catalase activities
in SV-40-transformed fibroblasts (Bravard et al., 1992;
Hoffschir et al., 1993), hormone receptors in breast cancer
(Magdelenat et al., 1994) and regulation of thymidylate
synthase and thymidine kinase syntheses in colorectal cancer
(Bardot et al., 1991; Lasserre, 1994).
Decreased HK-I activity accentuates the paradox of fewer
HK-I transcripts (about a third) in highly glycolytic tumours.
It must be argued that HK activity measured by the
technique used in the samples could detect HK-I, -II and
-III. These two isoenzymes (HK-II and -III) are of minor
importance in brain tissue. In addition, the gene dosage of
HK-I pleads for a lack of compensation by HK-II and -III
increased activity.
It is common knowledge that quantitative relationships
between transcription levels of enzymes and their activities
are not directly reliable. However, Fanciulli et al. (1994)
showed that transfection ofNIH-3T3 cells with a HK cDNA-
induced tumour increased HK synthesis and the activity of
the particulate cellular fraction 2-fold, raised the glycolysis
rate and accelerated growth rate.
In the mostly grade IV xenografted gliomas studied here,
the tHK activity was a mean 6.8-fold lower than that of
normal human brain tissue. Floridi et al. (1989) also showed
that tHK activity was lower in tumours than in normal brain.
In our series, both c- and mHK activities were lower in
gliomas than in control brain tissue, but to a lesser degree for
the latter. Thus, HK remained preferentially bound to
mitochondria in most of these xenografted tumours. In 11
of them, the mHK fraction represented more than 50% of
the tHK activity, whereas it was below 35% in the other
four. LDH activity, used as positive enzyme control,
remained stable in the xenografted gliomas compared with
normal brain tissue, and demonstrated that the gliomas
examined have selectively adapted their HK activity.
The elevated lactate-pyruvate ratio in the large majority
of the gliomas demonstrated a metabolic deviation. This
increased glycolysis was not dependent on t-, c-, or mHK
activity or mHK binding. Graham et al. (1985) showed that
tumoral mHK exhibited different kinetics, with an increased
maximal velocity of HK activity in glioblastoma cell lines.
High glycolysis was associated with an elevated ATP
content. These results are in agreement with data showing a
high rate of glycolysis in brain tumours (Floridi, 1989;
Macbeth and Bekesi, 1962). Significantly lower tHK activity
associated with increased ATP pools was previously described
in a series of 15 human gliomas (Lowry et al., 1983).
Anchorage of HK-I to mitochondrial porins favours its
access to ATP synthesised via oxidative phosphorylation in
the inner mitochondrial compartment (Arora and Pedersen,
1988; Laterveer et al., 1994). HK-I anchorage to mitochon-
drial porins could maintain them in 'open state', which
enables a continuous ATP flux for glucose phosphorylation
(McCabe, 1994). In addition, the HK-I anchorage could
prevent mHK from proteolysis and, so doing, increases
enzymatic protein half-life. Mitochondrial HK can assure
rapid and efficient generation of ADP, which is essential for
oxidative phosphorylation (BeltrandelRio and Wilson, 1991)
and, as such, is less down-regulated than cHK by G-6-P. The
HK-I balance between cytosolic and mitochondrial forms
depends on intracellular pH (pHi) (Miccoli et al., 1996). A
relative alkaline pH, is observed in gliomas as compared with
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human brain, enhancing HK binding to mitochondria. In
addition, low feedback regulation of tumoral mHK and its
quick transphosphorylation turnover could explain the high
rate ofglycolysis despite decreased c-, m- and t-HK activities.
Nevertheless, other mechanims might operate in glioma cells
to explain this high glycolysis. A decreased pool of
mitochondria as observed in all the gliomas studied, as
previously shown by Pedersen in highly glycolytic tumours,
could participate in this metabolic deviation (Pedersen, 1978).
Moreover HK-I responsible for initiating glycolysis may
approach its lowest limit in tumours, explaining the
responsiveness of xenogrfted gliomas to lonidamine in vivo
(Oudard, 1995). Disrupting the HK-I mitochondria binding
could constitute a new strategy for reducing glycolysis
without salvage by oxidative phosphorylation.
In conclusion, this study confirms the recurrent chromo-
some 10 loss in advanced gliomas. The elevated glycolysis
measured in these xenografted tumours cannot be explained
either by adaptation of the HK-I mRNA amount or HK-I
enzymatic activity. This increased level of glycolysis strongly
indicates that glucose remains the major source of energy in
gliomas. Paradoxically, a deficit in HK-I, one of the main
steps in the metabolic chain of glucose-utilising metabolism
has been demonstrated. Although this sharp drop in the
activity of this key enzyme might precede the loss of
chromosome 10, another phenomenon is possibly at work
in reflecting a metabolic differential between normal and
tumoral tissue.
Abbrvab
HK-I, hexokinase type I isoenzyme; t-, c- and mHK total,
cytosolic, mitochondria-bound hexokinase respectively; G-6P,
glucose 6-phosphate; GAPDH, glyceraldehyde-3-phosphate-dehy-
drogenase; LDH, lactate dehydrogenase; SCC, saline sodium
citrate; AU, arbitrary units; GBM, glioblastoma multiforme.
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